NEW YORK (GenomeWeb) – Cambridge Epigenetix and NuGen Technologies have partnered to integrate Cambridge's TrueMethyl technology for oxidative bisulfite sequencing with NuGen's sequencing library preparation kits.
The companies said that the agreement will enable Cambridge to focus on its epigenetic biomarker discovery programs, both in house and in partnership with biopharma companies, while strengthening NuGen's whole-genome and targeted enrichment systems for epigenetic sequencing.
In addition, the combined technologies will broaden the scope of accessible samples for the detection of epigenetic DNA modifications such as 5-hydroxymethylcytosine and 5-methylcytosine, which play important roles in gene regulation in disease occurrence and progression.
New products resulting from this partnership are anticipated by the end of the year and will be available directly from NuGen, the companies said.